Abstract:Purpose Bladder carcinoma is the most common urological malignancy in China. Gene mutation may be one of causes of carcinogenesis in the cancer. We therefore investigated the mRNA expression of RTKN gene in clinic malignant bladder carcinoma and explored the relationship between the novel gene and the cancer. Methods Total RNA was extracted from 33 surgically resected specimens of bladder carcinoma and 19 specimens of tumor-free bladder tissues. After the optimal reverse-transcription polymerase chain reaction condition was established, the mRNA expression levels of the RTKN gene in the lesions and tumor-free bladder tissues were examined semiquantitatively, and the relationships between expression levels of RTKN and clinical pathological features were analyzed. Results The expression of RTKN gene mRNA in 33 human bladder carcinoma tissues was significantly higher than that in 19 human tumor-free bladder tissues (0.937±0.103 vs. 0.350±0.082). The average ratio of RTKN expression in neoplasms to that in tumor-free bladder tissues was 0.350±0.164. Based on this ratio the 33 patients were divided into three groups: a downregulated expression group ( n =2), an upregulated expression group ( n =22), and an unchanged group ( n =9). Although the χ 2 test demonstrated a statistically nonsignificant differences in RTKN expression between tumor stages Ta, T 1 , and T 2 overall in the 33 human bladder carcinoma, the t test showed that there were statistically significant differences between solitary and multiple tumors, between the paired group aged younger or older than 70 years in 27 de novo bladder carcinoma patients, and between the groups with tumor larger or smaller than 2.25 cm 3 . Conclusions These results suggest that the RTKN gene is involved in bladder carcinogenesis and progression in bladder carcinoma, indicating that RTKN gene could be a molecular target in cancer therapy.

The Expression of Cytokeratin 19mrna and Its Clinical Significance in Bladder Carcinomas

Study of the Expression of CK20 and Ki67 on Cystitis Glandularis of the Urinary Bladder

Relationship Between the Expression of Cytokeratin 20 Mrna in Gastric Carcinoma Tissue and the Pathological Classifications

Expressions of cyclooxygenase-2 and epidermal growth factor receptor in transitional cell carcinoma of bladder and their correlation

THE EXPRESSION AND CLINICAL SIGNIFICANCE OF CYTOKERATIN 20 mRNA IN CENTRAL VEIN BLOOD OF PATIENTS WITH GASTRIC CANCER BY RT-PCR

[Expression and Clinical Significance of Nuclear Matrix Protein 22 and Cytokeratin 18 in Transitional Cell Carcinoma of the Bladder].

Expression of Med-19 in bladder urothelial carcinoma and its clinical significance

[Expression and Clinical Significance of Cytokeratin 19 in Bone Marrow of Patients with Breast Cancer].

The Detection and Its Clinical Significance of Cytokeratin 19 Mrna (CK19 Mrna) in Pelvic Lymph Nodes of Cervical Cancer Patients

Detection of Cytokeratin 19 Mrna in Peripheral Blood by RT-PCR in Patients with Renal Cell Carcinoma

Clinical Significance of Cytokeratin 19 Mrna in the Peripheral Blood of Non-Small Cell Lung Cancer

Increased levels of CK19 mRNA in oral squamous cell carcinoma tissue detected by relative quantification with real-time polymerase chain reaction.

Microarray study on the expression of p53,VEGF,E-cad and CK20 in bladder tumor

Expression and Significance of Bladder Cancer Specific Nuclear Matrix Protein 4 and Cytokeratin 19 Fragment in Urine of Patients with Bladder Cancer

The Clinical Significance of Detection of CK-20mRNA in Peripheral Venous Blood of Patients with Bladder Cancer

Expression of E-Cadherin and Α-Catenin in Bladder Transitional Cell Carcinoma and Its Clinical Significance

Expression and Clinical Significance of Tumor Associated Antigen MUC1 and Its Isoform MUC1/Y mRNA in Bladder Cancer

Association between clinical characteristics and expression abundance of RTKN gene in human bladder carcinoma tissues from Chinese patients

Expression of CK19-mRNA in Cancerous and Paracancerous Tissues and Peripheral Blood of Lung Cancer Patients by Real-time Fluorescent Quantitative RT-PCR and Its Clinical Significance

Detction of Cox-2 Protein and CK20 Mrna in Urine for the Diagnosis of Bladder Carcinoma

UCA1 Expression in Bladder Cancer and Its Clinical Significance